Emyria Completes $2.5m Placement
Released
Released
Announcement PDF
ASX Announcement
01 May 2023
Emyria completes $2.5m placement to advance MDMA-assisted
therapy delivery, pivotal trials and novel drug discovery
HIGHLIGHTS
Well-supported $2.5 million Placement to existing as well as new institutional and
strategic investors:
●
Joint lead managers Sixty Two Capital and Taylor Collison
●
Follow-on investment from Tattarang’s Tenmile Ventures
Funds raised will be used to:
●
Support delivery of MDMA-assisted and psilocybin-assisted therapy from July 1st
●
Advance pivotal clinical trials of Emyria’s Ultra-Pure cannabinoid products and;
●
Advance the preclinical screening for Emyria’s novel MDMA-inspired drug
discovery program being developed with the University of Western Australia
●
Working capital
Emyria Limited (ASX: EMD) (Emyria or the Company), a clinical stage biotech, is pleased to
advise that it has received firm commitments from sophisticated and strategic investors in a
well supported $2.5m placement jointly led by Sixty Two Capital and Taylor Collison (the
Placement).
Funds raised will be used to:
Support the delivery of MDMA-assisted therapy with leading trauma specialist centre The Pax Centre - from July 1st, 2023. Patient-ready MDMA supply has already been secured,
training has been scheduled with internationally renowned psychiatrist, Dr Ben Sessa and
Emyria’s care protocol is currently under ethics committee review. Emyria is establishing an
evidence-based, licensable care model for both MDMA- and psilocybin-assisted therapy that
can scale through partner sites. Funding from this Placement will help Emyria scope
additional clinical partnership opportunities.
Advance the currently active Phase 3 clinical trial supporting registration activities of
EMD-RX5 - an Ultra-Pure CBD over-the-counter treatment for anxiety and stress. Emyria has
signed a commercialisation Term Sheet with Aspen Pharmacare Australia that will generate
royalties for the Company pending successful registration.
Support the US, FDA registration preparations for Emyria’s high-potency, Ultra-Pure CBD
product, EMD-RX9.
Advance multiple preclinical screening programs for Emyria’s novel MDMA-inspired drug
discovery program being developed with the University of Western Australia.
Emyria ASX Announcement | 01 May 2023
1
Emyria’s Managing Director, Dr. Michael Winlo, said: “This $2.5m placement shows the
confidence of our strategic investors in Emyria’s vision and potential.
This investment enables us to advance multiple, innovative treatment development
programs as well as deliver scalable, evidence-generating psychedelic-assisted therapy
with our specialist partners. We are well set to deliver on our vision of improving the lives
of patients with mental health and neuroscience challenges while generating enduring
value for our Shareholders.”
Placement Details
The Placement is being conducted at an Offer Price of A$0.15 per share, representing a
11.76% discount to the last traded price on 21 April 2023 (A$0.17).
New Shares issued under the Placement will rank equally with the Company’s existing
shares on issue. Any shares issued on exercise of the New Options will rank equally with
the Company’s fully paid ordinary shares then on issue.
Participants to the Placement will also be issued 1 free unlisted EMD option for every new
Placement share subscribed. The unlisted options will have a $0.30 strike and an expiry
date 2 years from the date of issue (Attaching Options).
Options to be issued under the Placement will be issued in accordance with the
Company’s available 15% placement capacity pursuant to ASX Listing Rule 7.1. 16,666,666
New Shares will be issued under the Company’s available 10% ASX Listing Rule 7.1A
capacity given the issue price for the New Shares is not less than 75% of the 15-day VWAP
for the Company’s shares.
The Placement shares and the Options issue are expected to occur on Tuesday 09 May
2023. An Appendix 3B (Proposed issue of securities) has been released in relation to this
announcement.
As Joint Lead Managers to the Placement, Sixty Two Capital and Taylor Collison will receive
a 6% capital raising fee on funds raised under the offer by each respective manager.
Indicative Timetable
Event
Proposed Dates
Settlement under Placement
Monday, 08 May 2023
Allotment of New Shares and New Options
Tuesday, 09 May 2023
- This release has been approved by the Board of Emyria. FOR FURTHER INFORMATION
Dr. Michael Winlo
Managing Director
+61 (0) 8 6559 2800
mwinlo@emyria.com
Lexi O’Halloran
Investor Relations
+61 (0) 404 577 076
investors@emyria.com
Emyria ASX Announcement | 01 May 2023
Andrew Williams
Media Relations
+61 (0) 416 583 672
awilliams@emyria.com
Sufian Ahmad
Corporate Advisor
+61 (0) 412 316 162
info@62capital.com.au
2
RECENT TRACTION & UPCOMING MILESTONES
CLINICAL PROGRAMS
“direct-to-consumer”
Formulation
optimisation (RX5)
Phase 1 study done
Phase 3
commencement
Regulatory submission
Commercial strategy
Australia
PRE-CLINICAL + THERAPY PROGRAMS
“prescription medicine”
New Drug Discovery
Psychedelic-assisted therapy
Formulation optimisation
(RX7 > RX9)
Continuous creation
& screening
Protocols developed
Preclinical Screening
Program for Pain
First patent family filed
Clinical partnerships
US-focused
preclinical program
Real-World Data system
Metabolic studies
MDMA supply secured
Lead selection
Psilocybin-supply
secured
Phase 1
Pre-IND (FDA)
Pivotal trials
Commercial strategy Europe
Commercial strategy USA
Phase 1 trials
Global commercial strategy
Therapist training
First patient
Global commercial strategy
ABOUT EMYRIA | emyria.com
Emyria Limited is a clinical drug development and care delivery company focused on accelerating
drug development and improving patient outcomes in neuroscience and mental health via:
●
Drug Development: Multiple, proprietary, Ultra-Pure cannabinoid dose forms suitable for
registration against multiple indications. Emyria’s first dose form, EMD-RX5, is in Phase 3 trials.
●
New Drug Discovery: Inspired by MDMA, Emyria is developing one of the world’s largest
libraries of MDMA-like compounds with partner, the University of Western Australia.
●
Proprietary Real-World Data (RWD): Emyria gathers robust and ethically-sourced data with
patients cared for at Emyria’s own specialist clinical service (Emerald Clinics).
Emyria RWD can help support drug development and care model improvement.
This release has been approved by the Board of Emyria.
EMYRIA’S INTERACTIVE INVESTOR HUB
| Investorhub.emyria.com |Interact with Emyria’s announcements
and updates by asking questions and comments, which our team can respond to where possible.
CAUTIONARY NOTE ON FORWARD-LOOKING STATEMENTS Any statements in this press release about future
expectations, plans and prospects for the Company, the Company’s strategy, future operations, and other statements containing the
words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “will,” “would,” “could,”
“should,” “continue,” and similar expressions, constitute forward-looking statements. Actual results may differ materially from those
indicated by such forward-looking statements as a result of various important factors, including: the Company’s ability to successfully
develop its product candidates and timely complete its planned clinical programs and the Company’s ability to obtain marketing
approvals for its product candidates. In addition, the forward-looking statements included in this press release represents the
Company’s views as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company’s
views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the
Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing
the Company’s views as of any date subsequent to the date hereof.
Emyria ASX Announcement | 01 May 2023
3
Share your feedback
Discover